Equities analysts expect that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will report earnings per share of ($1.15) for the current quarter, Zacks reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.06) and the lowest is ($1.23). Atara Biotherapeutics posted earnings of ($0.63) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 82.5%. The firm is expected to report its next quarterly earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.08) to ($3.91). For the next year, analysts anticipate that the firm will report earnings of ($4.62) per share, with EPS estimates ranging from ($4.97) to ($4.27). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.05).

ATRA has been the topic of several recent research reports. ValuEngine lowered shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Canaccord Genuity set a $47.00 price target on shares of Atara Biotherapeutics and gave the company a “buy” rating in a report on Monday, August 7th. BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective for the company in a research report on Tuesday, August 22nd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $24.40.

Atara Biotherapeutics (ATRA) traded up $0.10 during trading hours on Monday, reaching $14.60. 165,600 shares of the company’s stock traded hands, compared to its average volume of 233,711. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $23.00.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $15.02, for a total value of $66,088.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares in the company, valued at $11,081,260.34. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gad Soffer sold 7,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $15.00, for a total transaction of $105,000.00. Following the completion of the transaction, the executive vice president now owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,388 shares of company stock valued at $733,884. Insiders own 16.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRA. Eagle Asset Management Inc. raised its position in shares of Atara Biotherapeutics by 17.8% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after purchasing an additional 225,367 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Atara Biotherapeutics by 617.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after purchasing an additional 173,184 shares during the last quarter. Neuberger Berman Group LLC raised its position in shares of Atara Biotherapeutics by 15.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after purchasing an additional 147,061 shares during the last quarter. Morgan Stanley raised its position in shares of Atara Biotherapeutics by 147.6% during the 1st quarter. Morgan Stanley now owns 175,058 shares of the biotechnology company’s stock worth $3,597,000 after purchasing an additional 104,369 shares during the last quarter. Finally, Artal Group S.A. raised its position in shares of Atara Biotherapeutics by 20.0% during the 3rd quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after purchasing an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 82.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/20/atara-biotherapeutics-inc-atra-expected-to-announce-earnings-of-1-15-per-share.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.